These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 17878397

  • 1. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
    Simonson W, Hauser RA, Schapira AH.
    Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
    [Abstract] [Full Text] [Related]

  • 2. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS, Herawati L, Wan Y, Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group.
    Mov Disord; 2009 Jan 15; 24(1):25-31. PubMed ID: 18846551
    [Abstract] [Full Text] [Related]

  • 3. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H, Emre M.
    Expert Rev Neurother; 2012 Feb 15; 12(2):119-31. PubMed ID: 22288667
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
    Müller T.
    Clin Neuropharmacol; 2013 Feb 15; 36(3):84-91. PubMed ID: 23673910
    [Abstract] [Full Text] [Related]

  • 5. Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
    Jann MW.
    Am J Manag Care; 2011 Oct 15; 17 Suppl 12():S315-21. PubMed ID: 22087552
    [Abstract] [Full Text] [Related]

  • 6. Levodopa-related wearing-off in Parkinson's disease: identification and management.
    Pahwa R, Lyons KE.
    Curr Med Res Opin; 2009 Apr 15; 25(4):841-9. PubMed ID: 19228103
    [Abstract] [Full Text] [Related]

  • 7. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R.
    J Am Med Dir Assoc; 2006 Sep 15; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [Abstract] [Full Text] [Related]

  • 8. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.
    Ann Neurol; 2010 Jul 15; 68(1):18-27. PubMed ID: 20582993
    [Abstract] [Full Text] [Related]

  • 9. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A, TC-INIT Study Group.
    Eur Neurol; 2005 Jul 15; 53(4):197-202. PubMed ID: 15970632
    [Abstract] [Full Text] [Related]

  • 10. [Long term experience with Stalevo in Szeged, Hungary].
    Klivényi P, Vécsei L.
    Ideggyogy Sz; 2009 May 30; 62(5-6):178-80. PubMed ID: 19579666
    [Abstract] [Full Text] [Related]

  • 11. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
    Tse W.
    J Am Med Dir Assoc; 2006 Sep 30; 7(7 Suppl 2):12-7. PubMed ID: 17948614
    [Abstract] [Full Text] [Related]

  • 12. Levodopa/carbidopa/entacapone in Parkinson's disease.
    Seeberger LC, Hauser RA.
    Expert Rev Neurother; 2009 Jul 30; 9(7):929-40. PubMed ID: 19589043
    [Abstract] [Full Text] [Related]

  • 13. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
    Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, Pavon N, Macias R, Luquin MR, Hernandez B, Grandas F, Gimenez-Roldan S, Tolosa E, Obeso JA.
    Neurologia; 2005 May 30; 20(4):180-8. PubMed ID: 15891947
    [Abstract] [Full Text] [Related]

  • 14. Other pharmacological treatments for motor complications and dyskinesias.
    Waters C.
    Mov Disord; 2005 May 30; 20 Suppl 11():S38-44. PubMed ID: 15822104
    [Abstract] [Full Text] [Related]

  • 15. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
    Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A, FIRST-STEP Study Group.
    Mov Disord; 2009 Mar 15; 24(4):541-50. PubMed ID: 19058133
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M, Leinonen M, Poewe W.
    J Neural Transm (Vienna); 2015 Dec 15; 122(12):1709-14. PubMed ID: 26347184
    [Abstract] [Full Text] [Related]

  • 17. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D.
    J Neural Transm (Vienna); 2005 Feb 15; 112(2):221-30. PubMed ID: 15503197
    [Abstract] [Full Text] [Related]

  • 18. Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.
    Hauser RA.
    Geriatrics; 2006 Sep 15; 61(9):14-20. PubMed ID: 16989543
    [Abstract] [Full Text] [Related]

  • 19. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O.
    Eur J Neurol; 2011 Mar 15; 18 Suppl 1():3-10. PubMed ID: 21255197
    [Abstract] [Full Text] [Related]

  • 20. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 15; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.